SG11201811209QA - Oral gastroretentive formulations and uses thereof - Google Patents
Oral gastroretentive formulations and uses thereofInfo
- Publication number
- SG11201811209QA SG11201811209QA SG11201811209QA SG11201811209QA SG11201811209QA SG 11201811209Q A SG11201811209Q A SG 11201811209QA SG 11201811209Q A SG11201811209Q A SG 11201811209QA SG 11201811209Q A SG11201811209Q A SG 11201811209QA SG 11201811209Q A SG11201811209Q A SG 11201811209QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- street
- pct
- rule
- english
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 229940065144 cannabinoids Drugs 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662360744P | 2016-07-11 | 2016-07-11 | |
| PCT/IL2017/050783 WO2018011798A1 (en) | 2016-07-11 | 2017-07-11 | Oral gastroretentive formulations and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811209QA true SG11201811209QA (en) | 2019-01-30 |
Family
ID=59388117
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202100182TA SG10202100182TA (en) | 2016-07-11 | 2017-07-11 | Oral gastroretentive formulations and uses thereof |
| SG11201811209QA SG11201811209QA (en) | 2016-07-11 | 2017-07-11 | Oral gastroretentive formulations and uses thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202100182TA SG10202100182TA (en) | 2016-07-11 | 2017-07-11 | Oral gastroretentive formulations and uses thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20190224118A1 (zh) |
| EP (1) | EP3481371A1 (zh) |
| JP (1) | JP2019527208A (zh) |
| KR (1) | KR20190026799A (zh) |
| CN (1) | CN109414403A (zh) |
| AU (1) | AU2017296351A1 (zh) |
| BR (1) | BR112018077541A2 (zh) |
| CA (1) | CA3027700A1 (zh) |
| CO (1) | CO2019000643A2 (zh) |
| IL (1) | IL264065A (zh) |
| MX (1) | MX2019000348A (zh) |
| NZ (1) | NZ750422A (zh) |
| PH (1) | PH12019500061A1 (zh) |
| RU (1) | RU2019103297A (zh) |
| SG (2) | SG10202100182TA (zh) |
| WO (1) | WO2018011798A1 (zh) |
| ZA (1) | ZA201900275B (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3582755A4 (en) * | 2017-02-15 | 2020-12-23 | Molecular Infusions, LLC | FORMULATIONS |
| BR102018002843A2 (pt) | 2018-02-09 | 2019-08-27 | Prati Donaduzzi & Cia Ltda | composição farmacêutica e uso da mesma |
| JP2021534821A (ja) * | 2018-08-20 | 2021-12-16 | ヘクソ・オペレーションズ・インコーポレイテッド | 制御されたカンナビノイドプロファイルのユーザー経験を有するカンナビス注入製品 |
| GB2584341B (en) | 2019-05-31 | 2023-03-01 | Gw Res Ltd | Cannabinoid formulations |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US20210177740A1 (en) * | 2019-12-11 | 2021-06-17 | Joel Studin | Transpore delivery of cannabinoid and uses thereof |
| WO2021137225A1 (en) * | 2020-01-02 | 2021-07-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Floating drug delivery systems comprising cannabinoids |
| CA3217137A1 (en) | 2021-04-29 | 2022-11-03 | Christopher Adair | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| WO2023272335A1 (en) * | 2021-06-30 | 2023-01-05 | Emyria | Cannabidiol formulation comprising a matrix pellet forming excipient |
| CN114796142A (zh) * | 2022-04-08 | 2022-07-29 | 黄山学院 | 萘普生胃漂浮片及其制备方法 |
| CN117224522B (zh) * | 2023-11-15 | 2024-02-23 | 北京协和药厂有限公司 | 药物组合物及其制备方法、药物制剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03163011A (ja) * | 1989-08-31 | 1991-07-15 | Yamanouchi Pharmaceut Co Ltd | 胃内滞留デバイス |
| IL133196A0 (en) * | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| US10004684B2 (en) * | 2001-02-14 | 2018-06-26 | Gw Pharma Limited | Pharmaceutical formulations |
| US9265724B2 (en) * | 2005-11-07 | 2016-02-23 | Ram B. Murty | Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
| EP1903866B1 (en) * | 2005-11-07 | 2016-04-06 | Murty Pharmaceuticals, Inc. | Improved delivery of tetrahydrocannabinol |
| LT2997953T (lt) | 2006-01-18 | 2019-02-11 | Intec Pharma Ltd. | Agento tiekimo įtaisas vartojimui per burną |
| SI2276473T1 (sl) | 2008-04-18 | 2017-02-28 | Intec Pharma Ltd. | Gastro retencijsko dajanje zdravila karbidope/levodope |
| WO2010064100A1 (en) * | 2008-12-04 | 2010-06-10 | Intec Pharma Ltd. | Baclofen gastroretentive drug delivery system |
| EP2490677A2 (en) | 2009-10-19 | 2012-08-29 | Intec Pharma Ltd. | Novel gastroretentive dosage forms of poorly soluble drugs |
| EP2635272A1 (en) * | 2010-11-01 | 2013-09-11 | Intec Pharma Ltd. | Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms |
| WO2013009928A1 (en) | 2011-07-11 | 2013-01-17 | Organic Medical Research | Cannabinoid formulations |
| EP2956133A4 (en) * | 2013-02-12 | 2016-12-21 | Corbus Pharmaceuticals Inc | ULTRAPURIC TETRAHYDROCANNABINOL-11-OIC ACIDS |
| US20150057342A1 (en) | 2013-08-21 | 2015-02-26 | Cannabics Pharmaceuticals Inc | Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof |
-
2017
- 2017-07-11 WO PCT/IL2017/050783 patent/WO2018011798A1/en unknown
- 2017-07-11 BR BR112018077541-0A patent/BR112018077541A2/pt not_active Application Discontinuation
- 2017-07-11 AU AU2017296351A patent/AU2017296351A1/en not_active Abandoned
- 2017-07-11 CA CA3027700A patent/CA3027700A1/en not_active Abandoned
- 2017-07-11 SG SG10202100182TA patent/SG10202100182TA/en unknown
- 2017-07-11 JP JP2018568785A patent/JP2019527208A/ja active Pending
- 2017-07-11 NZ NZ750422A patent/NZ750422A/en unknown
- 2017-07-11 US US16/316,390 patent/US20190224118A1/en not_active Abandoned
- 2017-07-11 MX MX2019000348A patent/MX2019000348A/es unknown
- 2017-07-11 EP EP17743090.7A patent/EP3481371A1/en not_active Withdrawn
- 2017-07-11 SG SG11201811209QA patent/SG11201811209QA/en unknown
- 2017-07-11 KR KR1020197002888A patent/KR20190026799A/ko not_active Application Discontinuation
- 2017-07-11 RU RU2019103297A patent/RU2019103297A/ru not_active Application Discontinuation
- 2017-07-11 CN CN201780041708.3A patent/CN109414403A/zh active Pending
-
2019
- 2019-01-02 IL IL264065A patent/IL264065A/en unknown
- 2019-01-09 PH PH12019500061A patent/PH12019500061A1/en unknown
- 2019-01-15 ZA ZA2019/00275A patent/ZA201900275B/en unknown
- 2019-01-23 CO CONC2019/0000643A patent/CO2019000643A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018011798A1 (en) | 2018-01-18 |
| AU2017296351A1 (en) | 2019-02-28 |
| SG10202100182TA (en) | 2021-02-25 |
| IL264065A (en) | 2019-01-31 |
| NZ750422A (en) | 2021-10-29 |
| CO2019000643A2 (es) | 2019-04-30 |
| ZA201900275B (en) | 2020-05-27 |
| CN109414403A (zh) | 2019-03-01 |
| CA3027700A1 (en) | 2018-01-18 |
| RU2019103297A (ru) | 2020-08-11 |
| MX2019000348A (es) | 2019-03-28 |
| JP2019527208A (ja) | 2019-09-26 |
| KR20190026799A (ko) | 2019-03-13 |
| PH12019500061A1 (en) | 2019-10-14 |
| BR112018077541A2 (pt) | 2019-04-30 |
| EP3481371A1 (en) | 2019-05-15 |
| US20190224118A1 (en) | 2019-07-25 |
| RU2019103297A3 (zh) | 2020-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
| SG11201810116VA (en) | Exosomes comprising therapeutic polypeptides | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201805072PA (en) | Nicotine powder delivery system | |
| SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201809534UA (en) | Methods of treating autoimmune disease using allogeneic t cells | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201902988UA (en) | Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof | |
| SG11201811580SA (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201903431SA (en) | Sstr-targeted conjugates and particles and formulations thereof | |
| SG11201906616VA (en) | Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201806127XA (en) | Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate | |
| SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| SG11201408509PA (en) | Racecadotril lipid compositions | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |